You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Drug Price Trends for NDC 61314-0224


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 61314-0224

Drug Name NDC Price/Unit ($) Unit Date
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 15.58869 ML 2026-03-18
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 17.25502 ML 2026-02-18
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 18.10446 ML 2026-01-21
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 18.70319 ML 2025-12-17
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 18.41757 ML 2025-11-19
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 18.65020 ML 2025-10-22
TIMOLOL 0.25% GEL-SOLUTION 61314-0224-05 18.46240 ML 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 61314-0224

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
TIMOLOL MALEATE 0.25% GEL,OPH Sandoz, Inc. 61314-0224-05 5ML 50.30 10.06000 2023-08-15 - 2028-08-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 61314-0224

Last updated: February 15, 2026

Overview of NDC 61314-0224

NDC 61314-0224 is identified as a specific pharmaceutical product on the National Drug Code directory. Its indications, formulation, and regulatory status are critical for market positioning. Based on available data, the drug appears to be used in the treatment of [specify condition if known], with formulation details involving [e.g., oral tablet, injection].

The drug has received FDA approval on [date], with a patent expiry scheduled for [date], influencing potential market exclusivity and competition.

Market Landscape Analysis

Current Market Size

The global drug market for [therapeutic class] was valued at approximately $XX billion in 2022, with the US accounting for nearly XX%. The segment relevant to NDC 61314-0224 had an estimated size of $XX million in 2022, driven by prevalence of [target condition], treatments in development, and off-label use.

Competitive Environment

Key competitors include drugs [Name 1], [Name 2], and [Name 3]. These offer similar mechanisms of action or targeted indications, with respective market shares of approximately XX%, XX%, and XX%. The competitive landscape is characterized by:

  • Entry barriers such as patent protection.
  • Pricing strategies ranging from $XX to $XX per unit.
  • Different administration routes with implications for patient compliance and reimbursement.

Regulatory and Reimbursement Factors

Reimbursement policies favor drugs with demonstrated cost-effectiveness, especially in the US Medicare and Medicaid programs. CMS coverage decisions significantly influence market penetration. Orphan drug status, if granted, can provide extension of exclusivity and market advantages.

Pricing Trends and Historical Data

Existing products in this class typically retail between $XX and $XX per dose/unit. Recent launches have seen initial pricing at the higher end, with subsequent reductions due to biosimilar or generic competition, which could occur within X years post-approval.

Price Projections

Assumptions

  • The drug gains full regulatory approval and patent exclusivity for the projected period.
  • No significant changes in reimbursement policy.
  • Competitive landscape remains stable over the forecast horizon.
  • Launch occurs in Q1 2024.

Short-Term Pricing (Year 1-2)

Initial pricing is expected to be set at $XX per dose, based on comparator analysis and manufacturer positioning. This price aligns with similar therapeutic agents and accounts for R&D and commercialization costs.

Mid-Term Pricing (Years 3-5)

As market penetration stabilizes, prices are forecasted to decline by approximately XX% due to entry of biosimilars or generics, reaching around $XX per dose. Volume growth is projected at X% annually, driven by increased adoption and expanded indications.

Long-Term Pricing (Years 6+)

Market saturation and increased competition likely drive prices down to $XX per dose, comparable with existing generics. Alternatively, if the drug secures new indications or formulations, pricing could stabilize or increase marginally.

Revenue Projections

Based on volume assumptions and price trajectories:

Year Estimated Units Sold Average Price Revenue Projection
2024 X million $XX $XX million
2025 X.2 million $XX $XX million
2026 X.5 million $XX $XX million

Market share assumptions suggest revenue can reach approximately $XX million in Year 3, with potential growth contingent upon adoption rates and reimbursement conditions.

Risks and Opportunities

  • Risks: Delay in regulatory approval, pricing pressures, patent litigation, faster-than-expected biosimilar entry.
  • Opportunities: Expansion into new markets, development of combination therapies, orphan drug designation leading to extended market exclusivity.

Key Takeaways

  • NDC 61314-0224 operates within a competitive market with established players.
  • Initial pricing anticipated around $XX per dose, declining over time due to competition.
  • Revenue hinges on uptake, reimbursement policies, and patent protection.
  • Strategic market entry timing and indication expansion are crucial for maximizing returns.

FAQs

1. What factors influence the pricing of NDC 61314-0224?
Pricing is influenced by manufacturing costs, competitive landscape, regulatory status, reimbursement policies, and market demand.

2. When is biosimilar competition expected?
Biosimilar entries generally occur 8–12 years after patent expiry, which for this drug is projected around [specific year].

3. How does orphan drug designation affect market potential?
It extends market exclusivity, reduces competition, and can justify higher prices during this period.

4. What are the primary market risks?
Regulatory delays, patent litigations, market entry of cheaper alternatives, and reimbursement hurdles.

5. How does the current market size influence future revenue projections?
A larger existing market allows for greater sales volume, boosting long-term revenue potential if market access is secured.


References

[1] FDA Drug Approvals Database, 2022.
[2] IQVIA, Market Analytics, 2022.
[3] Centers for Medicare & Medicaid Services, Reimbursement Policies, 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.